ArticleResearch square2026
Plasma Heparan Sulfate Structural Variation and Phenotypic Heterogeneity in Pediatric Acute Respiratory Distress Syndrome.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial glycocalyx (eGCX) shedding contributes to microvascular endotheliopathy in Acute Respiratory Distress Syndrome (ARDS) and is a potential underrecognized source of phenotypic heterogeneity. In pediatric ARDS (PARDS), we examined whether circulating heparan sulfate (HS) signatures, as readouts of eGCX shedding, capture inter-individual variability beyond other eGCX components and protein biomarkers, whether specific HS structural features are enriched, and whether they correlate with heparanase-1 (HPSE) activity. We retrospectively analyzed plasma samples (2018-2020) from children with and without PARDS. Mass spectrometry quantified glycosaminoglycans and sulfation subtypes alongside HPSE activity, while protein biomarkers were measured by multiplex assay. Among 46 children (36 PARDS, 10 no PARDS), principal component analysis identified three components explaining 63% of variance. The primary component (PC1) was driven by 6-
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.